Literature DB >> 3211467

Incidence of second neoplasms in patients with bilateral retinoblastoma.

J D Roarty1, I W McLean, L E Zimmerman.   

Abstract

The cumulative incidence of second neoplasms in 215 patients with bilateral retinoblastoma was calculated using the life-table method. Second tumors developed in 4.4% of the patients during the first 10 years of follow-up, in 18.3% after 20 years, and in 26.1% after 30 years. The 30-year cumulative incidence was 35.1% for the 137 patients who received radiation therapy compared with an incidence rate of 5.8% for the 78 patients who did not receive radiation. In the 137 patients who received radiation, second tumors developed both inside and outside the field of therapy. There was a 30-year incidence rate of second tumors of 29.3% within the field of irradiation and 8.1% outside the field. The rate outside the field of irradiation (8.1%) was similar to that observed in nonirradiated patients (5.8%). Our findings indicate that carriers of the retinoblastoma gene have an increased incidence of second tumors, and that the incidence rate is further increased in patients who receive radiation therapy.

Entities:  

Mesh:

Year:  1988        PMID: 3211467     DOI: 10.1016/s0161-6420(88)32971-4

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  30 in total

Review 1.  Chemotherapy for retinoblastoma: a current topic.

Authors:  P T Finger; G Czechonska; H Demirci; A Rausen
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  New and recurrent tumor foci following local treatment as well as external beam radiation in eyes of patients with hereditary retinoblastoma.

Authors:  E P Messmer; W Sauerwein; T Heinrich; W Höpping; D Klueter-Reckmann; N Bornfeld; H Sack; M Förster; W Havers
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

3.  Preimplantation genetic diagnosis for retinoblastoma predisposition.

Authors:  Seema Dhanjal; Georgia Kakourou; Thalia Mamas; Natasha Saleh; Alpesh Doshi; Sarah Gotts; Sarah Nuttall; Karen Fordham; Paul Serhal; Joy Delhanty; Joyce Harper; Sioban Sengupta
Journal:  Br J Ophthalmol       Date:  2007-08       Impact factor: 4.638

Review 4.  Efficacy and toxicity of radiation in preparative regimens for pediatric stem cell transplantation. II: Deleterious consequences.

Authors:  T D Miale; S Sirithorn; S Ahmed
Journal:  Med Oncol       Date:  1996-03       Impact factor: 3.064

Review 5.  Molecules, cancer, and the surgeon. A review of molecular biology and its implications for surgical oncology.

Authors:  J M Arbeit
Journal:  Ann Surg       Date:  1990-07       Impact factor: 12.969

Review 6.  Recommendations for Long-Term Follow-up of Adults with Heritable Retinoblastoma.

Authors:  Emily S Tonorezos; Danielle Novetsky Friedman; Dana Barnea; Machteld I Bosscha; Guillermo Chantada; Charlotte J Dommering; Pim de Graaf; Ira J Dunkel; Armida W M Fabius; Jasmine H Francis; Mary-Louise C Greer; Ruth A Kleinerman; Wijnanda A Kors; Suzanne Laughlin; Annette C Moll; Lindsay M Morton; Petra Temming; Margaret A Tucker; Flora E van Leeuwen; Michael F Walsh; Kevin C Oeffinger; David H Abramson
Journal:  Ophthalmology       Date:  2020-05-15       Impact factor: 12.079

7.  Factors influencing metastasis in retinoblastoma.

Authors:  J Hungerford
Journal:  Br J Ophthalmol       Date:  1993-09       Impact factor: 4.638

Review 8.  Putative non-Mendelian transmission of retinoblastoma in males: a phenotypic segregation analysis of 150 pedigrees.

Authors:  F L Munier; L Arabien; P Flodman; M A Spence; G Pescia; H P Rutz; A L Murphree
Journal:  Hum Genet       Date:  1994-11       Impact factor: 4.132

Review 9.  Factors in improved survival from paediatric cancer.

Authors:  J W Taub
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

10.  Malignant fibrous histiocytoma in a patient with history of treated retinoblastoma.

Authors:  Hind M Alkatan; Azzah Maktabi
Journal:  Saudi J Ophthalmol       Date:  2010-01-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.